Taking into account the localization of APJ in podocytes and Caspase‐3 suppression by Apelin‐13 in these cells, it is likely that stimulation of a podocyte apelinergic system accounts, at least in part, for the reported beneficial effects of this peptide in DKD. The gene discussed is APLNR; the disease is diabetic kidney disease.